Maurizio Zazzi
0000-0002-0344-6281
Publication & Citation Trends
Publications
0 total
Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing.
Cited by 0
Semantic Scholar
Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes.
Cited by 0
Semantic Scholar
96-week real-world effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in HIV-infected adults with pre-existing NRTI resistance: a retrospective cohort study.
Cited by 0
Semantic Scholar
Anti-cluster A and anti-p24 antibodies in people with multidrug-resistant HIV: Preliminary observations from the PRESTIGIO registry.
Cited by 0
Semantic Scholar
Comparison of diagnostic performances of HDV-RNA quantification assays used in clinical practice: Results from a national quality control multicenter study.
Cited by 5
Semantic Scholar
People with four-class drug-resistant HIV-1 may have low levels of intact DNA.
Cited by 0
Semantic Scholar
Teropavimab and zinlirvimab sensitivity in people living with multidrug-resistant HIV-1: data from the PRESTIGIO Registry
Cited by 1
Semantic Scholar
Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry
Cited by 0
Semantic Scholar
Research Topics
HIV Research and Treatment
(282)
HIV/AIDS drug development and treatment
(279)
HIV/AIDS Research and Interventions
(166)
Hepatitis C virus research
(58)
SARS-CoV-2 and COVID-19 Research
(34)
Affiliations
University of Siena
Università Cattolica del Sacro Cuore
University of Foggia
University of Rome Tor Vergata
Roma Tre University